Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Treatment of Unresectable HCC with HAIC, Tislelizumab, and Lenvatinib
NCT06463444Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC). Primary endpoint: Objective Response Rate up to 60 months. Started Jun 2024; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06463444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463444.